Alopecia Market

Global Alopecia Market Size (2024 to 2032)

The global alopecia market was valued at USD 10.42 billion in 2024. The market size is estimated to grow at a CAGR of 8.8% from 2024 to 2032 and will be worth USD 20.46 billion by 2032.

MARKET DRIVERS

Chronic disorders like cancer, rheumatoid arthritis, hypertension, Hormonal imbalance- polycystic ovary syndrome (PCOS), depression, high level of stress, increasing consumption of alcohol and tobacco, changing food habits, and chemotherapy-induced alopecia are primarily propelling the global alopecia market growth.

Among women, the increasing prevalence of PCOS contributes to recent market growth. The hormonal imbalance from this disorder affects the hair follicles, which is why it is expected to lead to alopecia and accelerate market growth. In addition, increased awareness programs for the treatment and management of alopecia, increased prevalence of alopecia conditions such as androgenic alopecia, alopecia areata, alopecia totalis, and others, and environmental factors such as sun damage and hard water damage are other key factors expected to contribute to the growth of the global alopecia treatment market.

Y-O-Y rise in the aging population is predicted to boost the alopecia market.

Increasing age leads to more hair loss, especially in men, which is the leading cause of this disease. Therefore, the senior population's need for hair loss treatment products is increasing significantly, which is expected to drive market growth. Poor eating habits are considered one of the main engines of growth. Hair growth is affected by malnutrition and micronutrient deficiencies, and this is also linked to the absence of certain nutrients in the body, such as vitamins and biotin. Body nutrient reservoir significantly impacts health, resulting in hair loss. According to the American Hair Loss Association, over 96% of hair loss cases in men can be attributed to androgenic alopecia. In addition, it is estimated that around 86% of men develop significant hair thinning before the age of fifty. According to the 2018 Census of Practice of the International Society for Hair Restoration Surgery results, more than 55% of men and women treated surgically by member physicians were between 30 and 50 years old. According to World Bank statistics, current health expenditure increased from 10% in 2010 to 12.2 in 2020. In addition, current health expenditure per capita increased from 495.77 USD in 2010 to 1,200.55 USD in 2019. The increase in healthcare expenditure, supported by the population's need for quality healthcare services, is also expected to contribute to the growth of the global alopecia market.

Furthermore, factors such as the increasing prevalence of diseases globally, technical advancements, and increasing health expenditure per capita are some of the factors expected to offer opportunities for the global alopecia treatment market during the forecast period. In addition, due to the increasing demand for combination therapies with higher efficiency and minimal side effects, cytokines and regenerative cell therapies are widely used to treat different types of alopecia. Furthermore, various drugs, such as corticosteroids and minoxidil, have other benefits; minoxidil is also used to treat enlarged prostate. In addition, many drugs are currently in late-stage clinical trials, which should offer growth possibilities to the market participants.

MARKET RESTRAINTS

However, factors such as the expensive drugs and possible side effects caused by the medicine, such as acne at the application site, scalp burn, facial hair growth, hair loss, inflammation, or pain at the root of the skin, are expected to restrain the development of the global alopecia market during the forecast period. In addition, alopecia medicine does not have immediate results; hence people are often discouraged from continuing the alopecia treatment, which challenges the market growth rate. Moreover, alopecia drugs in underdeveloped countries are less known due to poor healthcare infrastructure, which is expected to hamper the growth of the global alopecia market.

REPORT COVERAGE

SEGMENTAL ANALYSIS

Global Alopecia Market Analysis By Disease Type

Based on the disease type, the alopecia areata segment is expected to account for the largest share of the market during the forecast period. The Alopecia areata held a significant share over the forecast period of 35.2% in 2023. Consumer awareness, increasing disease prevalence, and technological advancements in treatment drive market growth. Due to a rise in the discovery of innovative therapies and positive efforts in the approval process, the category is expected to grow substantially during the projected period. For example, the U.S. FDA granted Incyte Corporation and Eli Lilly and Company Breakthrough Therapy Designation for baricitinib to treat A.A. in March 2020. The Breakthrough Therapy Designation will assist in obtaining clearance more quickly.

Global Alopecia Market Analysis By Treatment

Minoxidil dominates the global market and is expected to remain so during the forecast period. In addition, hair transplantation, scalp reduction treatment, and other surgical procedures can be used to treat alopecia. The proliferation of chronic diseases such as hypertension, depression, and arthritis drives segment growth. Moreover, an increase in air & water pollution is influencing the Alopecia treatment market as these pollutions harm the hair and result in baldness at the early stage.

Global Alopecia Market Analysis By Gender

The alopecia market is projected to be dominated by men during the forecast period, and this can be linked to the growing number of therapy options available to men worldwide. In addition, males have a higher prevalence of alopecia, which implies this market produces significant revenue. However, the female segment is expected to rise steadily during the analysis period. One of the critical elements encouraging growth in females is the increased desire for aesthetic appearance.

Global Alopecia Market Analysis By End Use

The dermatology clinics segment dominated the market, owing to factors such as an increase in the number of dermatology clinics and a rise in the number of trichologists worldwide. On the other hand, hospitals and physician's offices are expected to develop steadily over the predicted period. Positive growth is due to an increased number of patients seeking hair treatments at such medical facilities.

REGIONAL ANALYSIS

North America currently accounts for the most significant global market share during the forecast period. Due to the surge in hair loss among people and high treatment rates. Furthermore, due to the increased awareness of alopecia treatment products, Asia Pacific delivers lucrative prospects for Key players in the alopecia treatment market. On the other hand, the alopecia market in the Middle East and Africa is expected to rise significantly throughout the analysis period, owing to an increase in the number of hair treatments performed in the region.

In 2023, the North American alopecia market held 44% of the global market in U.S. revenue. The U.S. is expected to dominate the regional market, followed by Canada. The national alopecia areata recorded that in the United States, approximately 7.2 million people were diagnosed in 2018. The increasing technological advancements in the medical sector and the increase in research and development activities in the health sector are expected to drive the market for the North American region. Another factor expected to support market growth in the region is the increasing drug approval by the United States Food and Drug Administration (FDA).

The European alopecia market is expected to witness a healthy growth rate during the forecast period. The maU.K.ets in the U.K. and France accounted for the most significant share in the European alopecia market in 2019 and are expected to continue throughout the forecast period.

The alopecia market in the APAC region is projected to register the fastest growth rate in the global alopecia treatment market during the forecast period. This can be attributed to the increase in the geriatric population and unhealthy lifestyle changes among the people of this region. Furthermore, increasing cases of baldness in the region, mainly in countries like China and India, are additional factors that are expected to contribute to the growth of the alopecia market.

The alopecia market in the Middle East is estimated to grow at a CAGR of 7.06%. Since Dubai has the highest hair loss cases among other countries due to the climatic changes that are dry and dull, which makes the hair dehydrated and causes hair loss. Therefore, the demand and need for hair treatment increase are driving the market growth of alopecia treatment. The MEA region will have an excellent market growth rate owing to the increased adoption of alopecia treatment products, the significant presence of pharmaceutical companies, the developing healthcare infrastructure, and the availability of treatment products.

The alopecia market in Latin America is expected to experience a high growth rate during the forecast period, mainly due to medical tourism in Latin American countries such as Mexico, Argentina, Brazil, and Peru. Additionally, the developing healthcare sector, the rise of health reforms, and technological advances in the health field will expand the alopecia treatment market in the region.

KEY MARKET PLAYERS

Johnson & Johnson, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Cellmid Ltd., The Himalaya Drug Company, Taisho Pharmaceutical Holdings Co., Ltd, Shiseido Co., Ltd and Zhangguang 101 Science & Technology Co., Ltd are a few of the noteworthy companies in the global alopecia market.

RECENT MARKET DEVELOPMENTS

• In January 2018, Dr. Reddy Laboratories Ltd. launched HAIROOTZ in India. This product prevents excessive hair loss, provides minerals that reduce hair loss and breakage and prevents dandruff and graying.
• In January 2018, Teva Pharmaceutical Industries Ltd and Paxman collaborated on a new product- 'PAXMAN Scalp Cooler' to treat cancer patients in Mexico.
• In October 2019, Cellmid collaborated with Aeon International for evolis® Professional to expand the Chinese e-commerce market.

DETAILED SEGMENTATION OF THE GLOBAL ALOPECIA MARKET INCLUDED IN THIS REPORT

This research report on the global alopecia market has been segmented and sub-segmented into the following categories.

By Disease Type

• Alopecia Areata
• Cicatricial Alopecia
• Traction Alopecia
• Alopecia Totalis
• Alopecia Universalis
• Androgenetic Alopecia
• Others

By Treatment

• Pharmaceuticals
• Devices

By Gender

• Male
• Female

By Sales Channel

• Prescriptions
• OTC

By End Use

• Homecare Settings
• Dermatology Clinics

By Region

• North America
• Europe
• APAC
• Latin America
• Middle East and Africa